Meta Information

ID:igf-1-lr3

Name:IGF-1 LR3

Schema Version:1.5

Alternate Names

• Insulin-like Growth Factor 1 Long R3

Active Compound

IGF-1 LR3

Intervention Type

therapeutic_agent

Delivery

Route:

subcutaneous_injection

Scope:

• systemic

Regulatory Status

• us:research_chemical
• eu:unapproved_substance

Indication

Focus:

healthspan

Description:

Investigated for anabolic effects, but generally linked to mechanisms that may reduce longevity.

Typical Protocol

• Typically administered via subcutaneous injection in doses ranging from 20-100 mcg per day, often in cycles lasting several weeks.
• No established clinical protocol exists for healthspan application due to lack of regulatory approval and evidence.

Expected Cost Mean

Low Cost:

50

High Cost:

200

Cost Type:

monthly

Description:

Cost for a typical month's supply; generally not covered by insurance.

Summary

IGF-1 LR3 is a modified variant of Insulin-like Growth Factor 1 (IGF-1) designed with an extended half-life and reduced binding to IGF-binding proteins, leading to increased free IGF-1 activity. While IGF-1 signaling is essential for growth and tissue repair, chronically elevated levels are generally associated with increased risk of certain cancers and may negatively impact longevity pathways by suppressing cellular housekeeping mechanisms.

Purpose

Modified IGF-1; promotes anabolism, potentially compromises longevity signaling.

Drug Class

Insulin-like Growth Factors (IGFs)

Drugs In Class

Empty Array

Impact

Score:

0.5

Justification:

Chronic elevation of IGF-1 signaling is generally detrimental for longevity.

Evidence

Grade:

C

Score:

3

Justification:

Limited human data for LR3 specifically; none for healthspan benefits.

Safety

Score:

7.5

Justification:

Unregulated injectable peptide with potential for significant metabolic and oncogenic effects.

Flags

• Potentially increases risk of certain cancers, particularly with chronic use.
• May induce hypoglycemia, requiring careful monitoring.
• Risk of localized injection site reactions and infection.
• Long-term systemic effects on organ growth are not well characterized.
• Lack of regulatory oversight means product purity and dosage are often unreliable.

Verdict

Avoid for healthspan; significant risks outweigh unproven benefits.